PRMT5 is a Poor Prognostic Marker for NSCLC and Inhibition of PRMT5 Results in Increased Lung Cancer Sensitivity to Cisplatin and Radiotherapy

被引：0
|
作者：
Welliver, Meng [1 ]
Jin, Feng [2 ]
Otterson, Gregory [1 ]
Carbone, David [3 ]
机构：
[1] Ohio State Univ Ccc, Radiat Oncol, Columbus, OH USA
[2] Ohio State Univ, Radiat Oncol, Columbus, OH 43210 USA
[3] Ohio State Univ Ccc, Internal Med, Columbus, OH USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期
关键词：
D O I：
10.1016/j.jtho.2016.11.1144
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.01-092
引用
收藏
页码：S844 / S844
页数：1
相关论文
共 50 条
  • [21] Acquired resistance to PRMT5 inhibition induces concomitant collateral sensitivity to paclitaxel
    Mueller, Helen S.
    Fowler, Colin E.
    Dalin, Simona
    Moiso, Enrico
    Udomlumleart, Tee
    Garg, Salil
    Hemann, Michael T.
    Lees, Jacqueline A.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2021, 118 (34)
  • [22] Flavokawain A is a natural inhibitor of PRMT5 in bladder cancer
    Liu, Shuangjie
    Liu, Zhuonan
    Piao, Chiyuan
    Zhang, Zhe
    Kong, Chuize
    Yin, Lei
    Liu, Xi
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2022, 41 (01)
  • [23] PRMT5 regulates the chemoresistnace of ovarian cancer cells
    Do, Yen Thi
    Kim, Jin Young
    Lee, Seungmee
    Vo, Tam Thuy Lu
    Pham, Thi Tuyet Mai
    Ha, Eunyoung
    Cho, Chi-Heum
    Shin, So-Jin
    Seo, Ji Hae
    CANCER RESEARCH, 2023, 83 (07)
  • [24] Flavokawain A is a natural inhibitor of PRMT5 in bladder cancer
    Shuangjie Liu
    Zhuonan Liu
    Chiyuan Piao
    Zhe Zhang
    Chuize Kong
    Lei Yin
    Xi Liu
    Journal of Experimental & Clinical Cancer Research, 41
  • [25] Role of PRMT5 in bladder cancer: a comprehensive study
    Ma, Yingxin
    Zhong, Yucheng
    Huang, Weiren
    TRANSLATIONAL CANCER RESEARCH, 2019, 8 (02) : 491 - 498
  • [26] Decreased expression of PRMT5 is associated with prostate cancer
    Guo, CC
    Zhang, X
    Yee, H
    Chiriboga, L
    Melamed, J
    Lee, P
    MODERN PATHOLOGY, 2005, 18 : 143A - 143A
  • [27] Role of PRMT5 in neuroendocrine prostate cancer development
    Nam, Hye Seung
    Deng, Xuehong
    Hu, Chang-Deng
    CANCER RESEARCH, 2024, 84 (06)
  • [28] Decreased expression of PRMT5 is associated with prostate cancer
    Guo, CC
    Zhang, X
    Yee, H
    Chiriboga, L
    Melamed, J
    Lee, P
    LABORATORY INVESTIGATION, 2005, 85 : 143A - 143A
  • [29] PRMT5 selective inhibitor enhances therapeutic efficacy of cisplatin in lung adenocarcinoma cells
    Bajbouj, Khuloud
    Ramakrishnan, Rakhee
    Ihmaid, Ahmed M. H.
    Ali, Suhaib Al Haj
    Alalool, Abdulla
    Abdullah, Reem
    Saber-Ayad, Maha
    Hamid, Qutayba
    CANCER RESEARCH, 2019, 79 (13)
  • [30] INHIBITION OF PRMT5 SENSITIZES GLIOBLASTOMA MODELS TO TRAMETINIB TREATMENT
    Banasavadi, Yesh
    Namagiri, Sriya
    Otani, Yoshihiro
    Thammegowda, Shilpa
    Sur, Hannah
    Rivas, Sarah
    Bryant, Jean-Paul
    Chowdhury, Ashis
    Lewis, Cole
    Shimizu, Toshihiko
    Walbridge, Stuart
    Lee, Tae Jin
    Maric, Dragan
    Yoo, Ji Young
    Heiss, John
    Kaur, Balveen
    NEURO-ONCOLOGY, 2021, 23 : 79 - 80
12345